 |
Clinical Results of Teriparatide Treatment of Osteoporosis
Rui NIIMI
※1
Toshibumi KONO
※1
Kenji KURODA
※2
Haruyoshi MIZUNO
※2
Atsushi NISHIHARA
※1
Toshihiko KONO
※1
Akihiro SUDO
※3
※1 Department of Orthopaedic Surgery, Tomidahama Hospital
※2 Department of Rehabilitation, Tomidahama Hospital
※3 Department of Orthopaedic Surgery, Mie Graduate School of Medicine
Background:Once-daily injections of teriparatide increase bone formation and bone mass. The aim of this study was to evaluate the efficacy of daily subcutaneous teriparatide administration for 12 months.
Methods:Sixty-seven osteoporosis patients were enrolled in this study. The bone mineral density (BMD) of the lumbar spine and femoral neck was measured every four months. A bone formation marker 〔amino-terminal propeptide of type I procollagen (P1NP)〕 in the patients' serum and a bone resorption marker 〔cross-linked N-telopeptides of type I collagen (NTX)〕 in the patients' urinary were measured at baseline and at one month and four months after the start of treatment.
Results:Teriparatide treatment significantly increased the BMD of the lumbar spine by 11.4% at 12 months. The BMD of the femoral neck had increased by 0.8%. P1NP had increased rapidly at one month, and it remained high until four months. At four months, teriparatide treatment had significantly increased the average P1NP level by 403% and the average NTX level by 133%.
Conclusions:Teriparatide effectively increased both lumbar BMD and bone marker levels.
|
|
|
|
|
|
